Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
Rhea-AI Summary
Fennec Pharmaceuticals (NASDAQ: FENC) will release Q1 2026 financial results before U.S. market open on Thursday, May 14, 2026. Management will host a conference call and live webcast at 8:30 a.m. ET. A replay will be archived on the company website for 30 days.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – FENC
On the day this news was published, FENC declined 3.90%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $10M from the company's valuation, bringing the market cap to $251.15M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
FENC is up 6.85% while only one tracked peer (VNDA) appears in momentum scanners, moving down. Broader biotech peers show mixed, mostly modest moves, suggesting today’s strength is stock-specific rather than a sector-wide shift.
Previous Earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Earnings date announcement | Neutral | -3.7% | Set date and call details for FY2025 and Q4 2025 results. |
Prior earnings-date scheduling news saw a mild negative reaction of -3.74%, indicating some tendency for slight weakness around timing announcements.
Over recent months, Fennec has combined clinical and corporate milestones. It highlighted ASCO 2026 abstracts for PEDMARK and an investigator-sponsored Phase I/II study, granted inducement stock options covering 377,500 shares, and reported FY2025 net product sales of $44.6M with a $10.1M net loss. A prior earnings-date announcement on Mar 18, 2026 saw a -3.74% reaction. Today’s Q1 2026 earnings-date news continues its regular reporting cadence.
Historical Comparison
In the past 6 months, FENC had 1 similar earnings-date announcement with an average move of -3.74%. Today’s positive move of 6.85% contrasts with that prior mild downside reaction.
The company previously scheduled its FY2025 and Q4 2025 results call and is now setting the Q1 2026 results date, reflecting a steady quarterly reporting progression.
Market Pulse Summary
This announcement sets the timetable for Fennec’s Q1 2026 earnings release on May 14, 2026 with an 8:30 a.m. ET call. In recent months, the company reported FY2025 net product sales of $44.6M and a net loss of $10.1M, while advancing PEDMARK-related studies and option grants. Investors may watch upcoming results and any updated metrics on sales growth, cash balance, and operating trends.
AI-generated analysis. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.
Conference Call & Webcast Detail:
Date: Thursday, May 14, 2026
Time: 8:30 a.m. Eastern Time
Webcast Link: https://edge.media-server.com/mmc/p/2iptdco4
Participant Link: https://register-conf.media-server.com/register/BIaa4b518aeb974d02873eccf8f56d92f3
To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI.
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.
PEDMARK has received Orphan Drug Exclusivity in the U.S. and.; PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.
For more information, please visit www.fennecpharma.com and follow on LinkedIn.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
